Table 1 Studies that have assessed the role of FDG-PET in predicting the response of oesophageal cancer to neoadjuvant chemoradiation
From: Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation
Study + Reference | Path | Chemo | Radiotherapy | Second PET | Main Results |
|---|---|---|---|---|---|
Brucher et al, 2001 [82] | 24 SCC | 5 FU | 30 Gy/15# | 3 weeks after CRT | An SUV reduction of >52% led to sensitivity, specificity, positive and negative predictive values of 100%, 55%, 72% and 100% respectively |
Kato et al, 2002 [83] | 10 SCC | cis/5 FU | 40 Gy/20# | 2 weeks after CRT | Pathological response did not correlate with rate of reduction of SUV |
Arslan et al, 2002 [84] | 22 AD 2 SCC | See notes‡ | 40–50.4 Gy/20–28# | 4 wks after CRT | Change in volume identified responders. Quantitative evaluation of primary tumour pre and post therapy could not separate post therapy inflammation from residual tumour |
Flamen et al, 2002 [85] | 27 SCC 9 AD | cis/5 FU | 40 Gy/20# | 4–6 weeks after CRT | When >80% reduction in FDG tumour:liver uptake ratios used to define response sensitivity 71% and specificity 82% |
Downey et al, 2003 [86] | 26 AD 13 SCC | cis/taxol | 50.4 Gy/28# (2 had no RT) | After CRT (not specified) | SUV reduction >60% associated with non-significant disease-free and survival advantage compared to when reduction <60% |
Brink et al, 2004 [87] | 13 AD 7 SCC | cis/5 FU | 36 Gy/20# | 2–3 weeks after CRT | No correlation |
Swisher et al, 2004 [88] | 73 AD 10 SCC | See notes* | 50.4 Gy/28# | After CRT (not specified) | Pathological response correlated with post therapy SUV. Post therapy SUV > 4 was only pre-operative factor to correlate with decreased survival |
Wieder et al, 2004 [90] | 38 SCC | 5 FU | 40 Gy/20# | During CRT in 27 | Changes in SUV were significantly different between 2 groups |
Song et al, 2005 [89] | 32 SCC | cis/cape | 45.6/38#(BID) + 46 Gy/23#/5 wks | 4 weeks after CRT | Pathological response could be predicted when analysis limited to initial highly metabolic tumours |
Levine et al, 2006 [81] | 52 AD 9 SCC 3 UN | cis/5 FU | 50.4 Gy/28# | After CRT (not specified) | Reduction in SUV ≥ 10 associated with significant response |
Gillham et al, 2006 [91] | 29 AD 3 SCC | cis/5 FU | 40.05 Gy/15# 44 Gy/22# | After 1 week of CRT | Changes in SUV during treatment did not predict pathological outcome |